| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTD | Executive VP, Global R&D | Ordinary Shares | 1,387 | $13,496 | $9.73 | 17 May 2022 | Direct |
| TEVA PHARMACEUTICAL INDUSTRIES LTD | Executive VP, Global R&D | Restricted Share Units | 71,293 | 05 Mar 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 17 May 2022 | 1 | -$1,068,067 | 4 | Executive VP, Global R&D | 19 May 2022, 07:31 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 04 Mar 2022 | 10 | -$250,219 | 4 | Executive VP, Global R&D | 08 Mar 2022, 15:07 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 28 Feb 2022 | 3 | -$61,799 | 4 | Executive VP, Global R&D | 02 Mar 2022, 06:47 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 08 Feb 2022 | 4 | -$55,412 | 4 | Executive VP, Global R&D | 10 Feb 2022, 15:09 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 10 Aug 2021 | 1 | -$506,021 | 4 | Executive VP, Global R&D | 12 Aug 2021, 16:04 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 11 May 2021 | 3 | -$194,830 | 4 | Executive VP, Global R&D | 13 May 2021, 07:45 |